metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
lung cancer : non small cell (NSCLC) lung cancer : non small cell (NSCLC)
versus no control (uncontrolled study)
	entrectinib
	ALKA-372-001, STARTRK-1, STARTRK-2 (lung cancer), 2020 Lancet Oncol 2020 Feb;21(2):271-282. J Clin Oncol 2021 Apr 10;39(11):1253-1263. NCT02568267	DESC	lung cancer : non small cell (NSCLC)	entrectinib ≥ 600 mg orally once per day		Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer	161	NA	no results	no results
	larotrectinib
	Drilon (basket), 2018 Lancet Oncol 2020 Apr;21(4):531-540. N Engl J Med 2018 Feb 22;378(8):731-739. NCT02576431	DESC	lung cancer : non small cell (NSCLC), NTRK gene alteration	larotrectinib		TRK Fusion-Positive Cancers in Adults and Children	-/-	NA	no results	no results

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

DESC

lung cancer : non small cell (NSCLC)

entrectinib ≥ 600 mg orally once per day

Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

161

DESC

lung cancer : non small cell (NSCLC), NTRK gene alteration

larotrectinib

TRK Fusion-Positive Cancers in Adults and Children

-/-